Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide effects on beta-cell function in T2D
NCT02212067Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2014
- Primary completion
- May 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the serum insulin concentration time curve from 0 to 10 minutes after IVGTT and Area under the serum insulin concentration time curve from 10 to 120 minutes after IVGTT. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02212067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212067.